Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Propafenone
Drug ID BADD_D01856
Description An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Indications and Usage Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
Marketing Status approved
ATC Code C01BC03
DrugBank ID DB01182
KEGG ID D08435
MeSH ID D011405
PubChem ID 4932
TTD Drug ID D0J2KV
NDC Product Code 51407-478; 24979-086; 69680-130; 69680-131; 71205-942; 12598-6285; 71205-941; 24979-087; 24979-085; 51407-477; 71205-940; 69680-132; 51407-479
UNII 68IQX3T69U
Synonyms Propafenone | Propafenone Hydrochloride, (R)-Isomer | Rytmo-Puren | Rytmogenat | SA-79 | SA 79 | SA79 | Propafenone, (+-)-Isomer | Propafenone, (R)-Isomer | Propafenone, (S)-Isomer | Propamerck | Apo-Propafenone | Baxarytmon | Cuxafenon | Fenoprain | Jutanorm | Nistaken | Prolecofen | Propafenon AL | Propafenon Hexal | Propafenone Hydrochloride | Hydrochloride, Propafenone | Propafenone Hydrochloride, (S)-Isomer | Rythmol | Propafenon Minden | Norfenon | Pintoform | Rytmonorm | Arythmol
Chemical Information
Molecular Formula C21H27NO3
CAS Registry Number 54063-53-5
SMILES CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Type III immune complex mediated reaction10.01.03.0230.000418%Not Available
Haemorrhage24.07.01.002--Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.003--Not Available
Pulseless electrical activity02.03.04.0200.000418%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Antinuclear antibody positive13.06.01.003--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush08.01.03.027; 24.03.01.005; 21.02.02.001--
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Peripheral embolism24.01.02.005--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Cardioactive drug level above therapeutic13.17.01.003--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.001--
Urine analysis abnormal13.13.02.008--Not Available
Breath sounds abnormal13.15.01.008--Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene